Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

355

Participants

Timeline

Start Date

January 26, 2020

Primary Completion Date

January 13, 2021

Study Completion Date

February 11, 2021

Conditions
Uncontrolled Type 2 Diabetes Mellitus
Interventions
DRUG

CPL-2009-0031 140 mg

Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.

DRUG

Sitagliptin 100mg

Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.

Trial Locations (12)

70001

Life Line Diagnostic Centre cum Nursing Home, Kolkata

302015

Bhandari Clinic & Research Centre, Jaipur

334001

S.P. Medical College and A.G. Hospital, Bikaner

382428

Apollo Hospital International Ltd, Gandhinagar

390001

SSG Hospital, Vadodara

421004

Ashirwad Hospital & Research Centre, Ulhasnagar

422002

Dhadiwal Hospital, Nashik

524004

A C Subba Reddy Government Medical College and Hospital, Nellore

560043

Bangalore Diabetes Centre, Bangalore

700014

Nilratan Sircar Medical College & Hospital, Kolkata

781006

Downtown Hospital, Guwahati

226010,

Sanjivini Lung Centre, Lucknow

Sponsors
All Listed Sponsors
collaborator

New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India

UNKNOWN

lead

Cadila Pharnmaceuticals

INDUSTRY

NCT04801199 - Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter